Annual Report

Overview

The report presents FY16 as a year of 14% consolidated revenue growth to ₹35,699 million and the first Japanese approval for Biocon's Insulin Glargine biosimilar. It highlights Syngene's successful IPO and listing, which pushed its market capitalization above USD 1 billion within a week. The company also reports CSR delivery across primary healthcare, education and sanitation, including screening more than 8,500 individuals for oral cancer and improving nutrition for over 1,200 children.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2015-2016
Period: 1 April 2015 – 31 March 2016
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services